Innovative drug out-licensing deal value vs Antibody-drug conjugate trial starts in China
In 2025, innovative drug out-licensing deal value in China was 130 billion USD; antibody-drug conjugate trial starts was 177.
Change the pair
Compare different indicators
The series
Over time
China, annual figures, spaced by time from 2024 to 2025 . Different units, drawn on separate scales and clipped to the years both series publish; earlier history stays on each indicator’s own page. Read the values, not the heights.
Innovative drug out-licensing deal value
Unit: billion USD · 2 observations
Antibody-drug conjugate trial starts
Unit: count · 2 observations
Shared periods
Side by side
2 periods are published for both series in China as annual figures on the same basis. Comparing anything else would mean comparing different periods.
| Period | Innovative drug out-licensing deal value | Antibody-drug conjugate trial starts |
|---|---|---|
| 2024 | 51.9 billion USD NHSA | 150 ClinicalTrials.gov |
| 2025 | 130 billion USD NHSA | 177 ClinicalTrials.gov |
Provenance
Where these numbers come from
Innovative drug out-licensing deal value
Total monetary value of out-licensing agreements signed for innovative pharmaceutical products.
2 observations charted in China · source organisations: NHSA
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
2 observations charted in China (of 6 annual records) · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring